Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics granted 19,865 inducement stock options to two new employees at a $8.88 exercise price with multi-year vesting terms.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xilio Therapeutics (XLO) granted non-qualified stock options to purchase 19,865 shares of common stock to two new employees, effective September 1, 2026, under its 2022 Inducement Stock Incentive Plan.
The options have an exercise price of $8.88 per share, equal to the closing price on September 1, 2026, and a ten-year term. Vesting covers 25% of the shares on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. The awards were approved as inducement grants under Nasdaq Listing Rule 5635(c)(4) and are governed by the plan and individual stock option agreements.
Details
News Market Reaction – XLO
On Sep 3, the first trading day after this news, XLO closed 2.04% above the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Shares under options
- 19,865 shares
- Granted to two new employees
- Grant date
- September 1, 2026
- Effective date of the option grants
- Exercise price
- $8.88 per share
- Equal to the September 1, 2026 closing price
- Option term
- Ten years
- Term of each stock option
- Initial vesting
- 25%
- Vests on the first anniversary following employment commencement
- Remaining vesting
- 75% in 36 equal monthly installments
- Subject to continued service
- Listing rule
- Nasdaq Listing Rule 5635(c)(4)
- Inducement material to entering employment
Historical Context
-
Quarterly results, pipeline updates, and cash runway disclosure
-
Options granted to three new employees under inducement plan
-
Ben Harshbarger appointed chief legal officer
-
Revenue growth, narrower loss, cash runway, and AbbVie milestone
-
Option granted to newly hired employee under inducement plan
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor Contact
Alex Lobo, Precision AQ
Alex.lobo@precisionaq.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did Xilio Therapeutics (XLO) grant on September 1, 2026?
Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees, effective September 1, 2026, under its 2022 Inducement Stock Incentive Plan.
What is the exercise price and term of the new Xilio Therapeutics (XLO) inducement stock options?
The inducement stock options have an exercise price of $8.88 per share, equal to the closing price on September 1, 2026, and each option has a ten-year term.
How do the Xilio Therapeutics (XLO) inducement stock options vest for the new employees?
Each option vests as to 25% of the shares on the first anniversary of employment. The remaining 75% vests in 36 equal monthly installments, subject to continued service with Xilio Therapeutics or its subsidiaries.
Under which plan and Nasdaq rule were the Xilio Therapeutics (XLO) inducement grants made?
The grants were made under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan as an inducement material to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).